Kanarb Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Full Prescribing Info

Adverse Reactions

The safety of Kanarb Tablets was evaluated in 406 patients, who had received Kanarb Tablets at the dose range of 60 to 120 mg for 4 to 12 weeks, out of a total of 852 patients with essential hypertension, enrolled in clinical trials and eligible for safety analysis (i.e., the safety database). There were 85 patients that received Kanarb Tablets for 6 months or longer. Most adverse events were mild to moderate, transient, and the occurrence rate was not related to dosage. The most frequently reported adverse events were headache and dizziness. Adverse reactions are summarized below (i.e., adverse events considered to be definitely related, probably related, or possibly related to Kanarb Tablets), reported in the clinical trials of Kanarb Tablets. (See Table.)

Click on icon to see table/diagram/image

View ADR Monitoring Form

Kanarb Adverse Reactions

Manufacturer:

Boryung Pharm

Distributor:

Zuellig Pharma